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httpcense.Abstract The clinical course of COPD is punctuated by acute exacerbations that have been deﬁned
as ‘‘a acute sustained worsening of the patient’s condition, from the stable state, and necessitates a
change in the regular medications.The cause of an acute exacerbation of COPD (AECOPD) is most
often infectious and related to a viral and/or bacterial infection. Gram negative bacteria started to
be a considerable etiology for AECOPD. The rational of the current study is to determine the Gram
negative bacterial etiology of AECOPD in hospitalized patients in our institution and assess the
incidence of multidrug resistance gram negative bacteria. 27 patients, 25 males and 2 females aged
with a mean age of 62.6 years were included in the study. A detail history was elicited and complete
examination was done. The sputum specimen was collected using sterile containers and subjected to
Gram’s stain, culture on blood agar. Sputum culture for pathogenic bacteria showed one or two
isolates in 10 cases (37%) and mixed ﬂora in 9 cases (33.3%), and there were no growth in 8 cases
(29.7%). Gram negative bacilli 25.9% were more isolated than Gram positive cocci 11.1%.
The commonest isolate was Pseudomonas aeruginosa 3 (11.1%), followed by Klebsiella pneumo-
niae 2 (7.4%). The drug sensitivity reveals that the gram negative isolates were sensitive to Carba-
penems (100%) followed by Aminoglycosisdes like Amikin. Multidrug resistant strains were only
found in 28.6% of the gram negative organisms and 7.4% of the total cases of AECOPD. To con-
clude Gram negative bacteria were more frequently isolated in our patients, antimicrobial treatment
should be started early depending on the antimicrobial sensitivity results, in the wake of an increas-
ing rate of isolation of resistant organisms.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V.Open access under CC BY-NC-ND license.011 222 999 19; fax: +20
(R.I.M. ElKorashy).
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Chronic obstructive pulmonary disease (COPD) is a group of
progressive, debilitating respiratory conditions, including
emphysema and chronic bronchitis, characterized by difﬁcult
breathing, lung airﬂow limitations, cough, and other
symptoms [1].is. Production and hosting by Elsevier B.V.
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bations that have been deﬁned as ‘‘a sustained worsening of
the patient’s condition, from the stable state and beyond nor-
mal day-to-day variations, that is acute in onset and necessi-
tates a change in regular medication in a patient with
underlying COPD’’ [2]. They can also be deﬁned by more read-
ily recalled events requiring health-care utilization (HCU) that
result in a therapeutic intervention (usually treatment with
antibiotics and/or oral corticosteroids [3].
The cause of an acute exacerbation of COPD (AECOPD) is
most often infectious and related to a viral and/or bacterial
infection [4]. The predictor of an exacerbation in any given pa-
tient appears to be a history of previous exacerbations [5]. The
mean number of exacerbations/year has been reported to be
2.3 in mild to moderate COPD, compared to 3.2 for patients
with more severe disease [6]. It has been suggested that patients
with frequent exacerbations (e.g., P2 per year) may represent
a distinct phenotype of COPD [7].
Haemophilus inﬂuenzae is the most frequent bacterium iso-
lated in all series followed by Streptococcus pneumoniae, and
Moraxella catarrhalis [8]. Others stated that the organism com-
monly play pathogenic role in acute exacerbations of COPD
are Pseudomonas and Klebsiella, Acinetobacter, M. catarrhalis
and Enterobacter [9].
Several recent studies have reported the presence of multi-
drug-resistant bacteria at hospital admission in patients with
severe COPD exacerbations [10]. Nonfermenting Gram-nega-
tive bacilli, including Pseudomonas aeruginosa, Acinetobacter
baumannii and Stenotrophomonas maltophilia, are the most fre-
quently isolated multidrug-resistant bacteria in severe COPD
exacerbations [11]. Multidrug-resistant bacteria were deﬁned
as, ceftazidime- or imipenem-resistant P. aeruginosa, A. bau-
mannii, S. maltophilia and extended-spectrum b-lactamase pro-
ducing Gram-negative bacilli [12].
Rationale
The goal of the study is to assess the incidence of gram nega-
tive bacterial organisms as a cause of AECOPD in the study
population, and the incidence of multidrug resistance in the
gram negative isolates if present according to the previously
mentioned deﬁnition [12].
Methodology
This cohort prospective observational study started at the
beginning of 2012 and included number of COPD patients
who was admitted with AE COPD over a period of 1 year, in
the Chest department, faculty of Medicine, Cairo University.
Inclusion criteria
 COPD patients diagnosed according to GOLD [13].
 Manifestations of infective exacerbations: Anthonisen crite-
ria: Worsening of COPD symptoms for P2 consecutive
days based on a patients report of worsening of at least 2
major symptoms (dyspnea, sputum volume and/or sputum
color) or the occurrence of at least one minor symptom
(sore throat, coryzal symptoms, otherwise unexplained
fever and/or worsening cough or wheeze. [14].Exclusion criteria
 Outpatient status.
 Treatment with any antibiotic within 48 h before admission.
 Absence of an adequate sputum specimen as determined by
Gram stain.
 Evidence of bronchiectasis.
 Need for mechanical ventilation.
For all the patients, the following will be obtained
 History taking and examination.
 Radiology: Chest X ray.
 Other diagnostic and radiological procedures may be needed
for assessment of the condition or to exclude other diagnoses.
 Complete blood picture to assess the total leukocytic count.
 Morning sputum sample in a sterile container, collected in
as in the ﬁrst 48 h of admission after noting the physical
properties. Direct ﬁlm by Gram stain will be done and rou-
tine sputum culture on blood agar, chocolate agar, Mc.con-
key media. The media were incubated at 37 C and
incubation of Chocolate agar in Co2 enriched atmosphere.
Sensitivity tests were done. The antibiotic impregnated discs
(Oxoid) were placed on freshly prepared lawn of bacterial
isolate on Mueller Hinton agar plates, and incubated at
35 ± 1 C for 24 h.
 The following should be put in consideration:
A reliable specimen has epithelial cells fewer than 10 per
100· ﬁeld. An unreliable sample can be misleading and is re-
jected by the laboratory, and requires sample repetition within
the ﬁrst 48 h [15]. A normal Gram stain of sputum contains
polymorphonuclear leukocytes, alveolar macrophages, and a
few squamous epithelial cells and shape of the organisms.
The normal respiratory ﬂora includes Neisseria catarrhalis,
Candida albicans, diphtheroids, alpha-hemolytic streptococci,
and some staphylococci. The presence of normal ﬂora does
not rule out infection [16].
Results
Forty-ﬁve COPD Patients were admitted with AECOPD, 42
males and 3 females. Only 27 patients out of the total number
of COPD patients 45 had infective exacerbations, and will be
considered the actual study population.
Diagnosing infective exacerbation, is based on Anthonisen
criteria [14].
According to the deﬁnition of multidrug resistant organisms
Ceftazidime resistance and/or imipenim resistance:
2/7 with a percent (28.6% of the gram negative organisms)
2/27 with a percent (7.4% of the total cases of COPD with
infective exacerbation)
Discussion
A cohort prospective observational study started at January
2012 for one year, in Chest department Cairo University and
Table 1 Study population.
Total No. of patients No. of patients with infective exacerbation
45 27 (60%)
Table 2 Demographic data.
Male:female 25:2
Smokers:non smokers 25:2 (1male:1 female)
Mean age in years 62.6
Table 4 Gram stain: epithelial cells.
No of epithelial cells <10/LPF 27/27 100%
>10/LPF 0/27 0%
Table 5 Gram stain: pus cells.
No of pus cells >25/LPF 15/27 55.5%
10–25/LPF 7/27 26%
<10/LPF 5/27 18.5%
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acute exacerbations and fulﬁlling the inclusion and exclusion
criteria.
Forty ﬁfe COPD patients were admitted to the chest
department, where only 27 patients (60%) considered as hav-
ing acute infective exacerbations (Table 1). The diagnoses of
acute infective exacerbation is based on the presence of fever,
changes in the sputum characters (amount, color and viscos-
ity), increased TLC, and/or radiological evidence of pneumo-
nia. The percentage of infective exacerbation was 60%, it
was found concordant with the mentioned range 50–70% gi-
ven by Ball [17] and by Lode et al. (62.6%) [18].
The mean age of COPD cases with infective exacerbation in
the current study was: 62.6 years, (Table 2), due to the fact that
chronic bronchitis has highest prevalence in ﬁfth and sixth dec-
ade [19]. Moreover the known mean age was around 70 [20,21].
The gender distribution: male:female 25:2 (Table 2), with a
female percentage of 7.4%, because smoking habits are more
pronounced in males [19]. However it is known that COPD
has increasingly prevalence among women [22]. And it may
reach even more than half the population of the AECOPD
requiring hospitalization (53.9%) in some studies [23].
The most common symptom was colored sputum 24/27
with% 89%, followed by dyspnea 22/27 with% 81.5%, (Ta-
ble 3) as was stated in the deﬁnition of acute exacerbation by
Anthonisen et al. [14].
Increased TLC was not predominant in most cases in the
current study 33.3% (Table 3). Some studies disagreed that
WBC elevates in COPD, because it was found a normal
WBC count [24]. On the other hand, Sin et al. stated that
blood WBC were elevated in a directly proportional manner
with severity of exacerbation [25], due to the systemic inﬂam-
matory burden [26].
The presence of pneumonia was only in 6/27 cases repre-
senting 22.2% (Table 3). There is debate over whether people
with AECOPD and coexistent pneumonia should be included
in the deﬁnition of AECOPD. However, pulmonary consolida-
tion was not exclusion in the major UK national audits of
COPD exacerbations [27]. COPD exacerbations that areTable 3 Clinical, laboratory and radiological ﬁndings.
No. of patients with fever
No. of patients with dyspnea
No. of patients with colored sputum
No. of patients with increased sputum viscosity.
No. of patients with increased TLC (above 11000/mm3)
No. of patients with radiological evidence of pneumoniaassociated by radiographic consolidation have the same dis-
ease severity when compared with non-pneumonic exacerba-
tions [28]. It may represent a percentage ranges from 8% [29]
to 33% [30].
Gram stain was performed for the specimens for rapid diag-
nosis of bacterial infections [30]. Assessment of the number of
epithelial cells was done to ensure reliability of the whole spec-
imens of the study population (Table 4). The amount of pus
cells in the smear (Table 5), represents the bacterial load in
the specimen and the intensity of infection, as it results from
dead white blood cells, debris from other damaged cells and
tissue, and bacteria [31].
Cultures with one or two isolates appeared in 10/27 cases
with a percentage 37% (Table 6). Different percentages of cul-
tured organisms appeared in similar studies like 38.29% [20],
46% [32], 55% [19], 56% [31] 65% [21]. Culture positivity de-
pends on nature of sputum, transportation time and the num-
ber of organism present in the sample [33].
Gram negative bacilli outnumbered the growth of other
organisms. The cultured gram negative bacilli were found in
7 out of 27 specimens with a percentage of 25.9% (Table 6).
However it was found 53.3% in other study [21], 34% in an-
other one [19]. The most common is P. aeruginosa (3 cases
out of 10 cultured specimens by one or two isolates), with a
percent of 30% like Ferrer et al. [34], (Table 7) compared to
nearly 25% in Chawla et al. [33] and Bari et al. [21], 21.7%
in Ye et al. [35], 20% in Patel et al. [36], and 15% in Madhavi
et al. [19].
This was followed by Klebsiella pneumonia (2 cases out of
10), with a percentage of 20% compared to 12.3% in Ye et al.
[35], 13.3% in Bari et al. [21]. And 59% in Madhavi et al. [19],
and I was considered the commonest isolate in his study.
Other gram negative isolate was A. baumannii, which was
found alone in 1 case (10%) compared to 7.8% in Ye et al.
[35] and 6.9% in Lin et al. [37] and combined with Pseudomo-
nas in another case (10%).
The antibiotic sensitivity (Tables 8 and 9) showed 100%
resistance to penicillins, minimal resistance to aminoglycosides
(Amikin) 14.3%, and considerable resistance to ﬂuroqinolones







Gram positive cocci Gram negative bacilli Mixed ﬂora No growth
No % No % No % No %
3/27 11.1 7/27 25.9 9/27 33.3 8/27 29.7
Thus the number of cultures with one or two isolates: 10/27 with a percent 37% of the total cultured specimens.
Table 7 Percentage of the cultures of gram negative bacterial isolates.
Gram negative Bacilli (No = 7)








Pseudomonas aeruginosa+ Acinitobacter baumannii
11.1%of total cases 7.4% of total cases 3.7% of total cases 3.7% of total cases
Table 8 Pattern of drug sensitivity in gram negative isolates.
Organisms P C1 C2 C3 A Q TS PB C
Pseudo. aeru. (ESLB) R R R R S S R S S
Pseudo. aeru. R R S S S R S R S
Pseudo. aeru. R S S S S R R R S
Klebsiella pneumoniae R R S S S S R S S
Klebsiella (ESLB) R R R R S S R S S
Acineto.baum. R R R S R R R S S
Acineto baum. and pseud. aeru. R R S S S R S S S
P: penicillins; C1: ﬁrst generation cephalosporin; C2: second generation cephalosporin; C3: third generation cephalosporin; A: aminoglycosides;
Q: quinolones; TS: trimethoprim/sulfamethoxaol; PB: polymyxins; C: carbapenems; ESLB: extended spectrum b lactamase.
Table 9 No. of resistance to different antibiotics.
P C1 C2 C3 A Q TS PB C
7/7 6/7 3/7 2/7 1/7 4/7 5/7 2/7 0/7
100% 85.7% 42.85% 28.6% 14.3% 57.1% 71.4 28.6% 0%
348 R.I.M. ElKorashy, R.H. El-SherifRegarding the third generation cephalosporin a resistance
of 28.6% of the total gram negative organisms, 7.4% of pa-
tients and 20% of all cultured bacteria thus they are considered
multidrug resistant organisms [12]. The resistant isolates were
ESbL producing Pseudomonas and Klebsiella. Carbapenems
are considered to be the antibiotics of choice for ESBL infec-
tions [38].
However in other studies, P. aeruginosa, and A. baumannii
are the most frequently isolated multidrug-resistant bacteria in
severe COPD exacerbations [12,34]. These bacteria were found
in 8% of patients and represented 24% of all bacteria [12].Conclusion and recommendations
P. aeruginosa and Klebsiella pneumoniae are the most common
sputum pathogens in hospitalized patients with AECOPD.
Carbapenems followed by aminoglycosides were the most
active antibacterial agents and, therefore, the drugs of choice
in treating AECOPD in our setting.The number of resistant strains causing acute exacerbations
are also increasing, so antimicrobial sensitivity pattern must be
checked for the causative organism.
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